Pretreatment with alkylating agents predicts for tumor cell content and CD34(+) stem cell yield in leukapheresis products of patients with multiple myeloma

Ähnliche Einträge

• A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells
  von: Cremer, Friedrich Walter, et al.
  Veröffentlicht: (1997)
• Estimation of the progenitor cell yield in a leukapheresis product by previous measurement of CD34+ cells in the peripheral blood
  von: Möhle, Robert, et al.
  Veröffentlicht: (1996)
• Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma
  von: Hundemer, Michael, et al.
  Veröffentlicht: (2014)
• Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone
  von: Cremer, Friedrich Walter, et al.
  Veröffentlicht: (1998)
• CD34 selection for purging in multiple myeloma and analysis of CD34+ b cell precursors
  von: Frühauf, Stefan, et al.
  Veröffentlicht: (1994)